EMA proposes waiving comparative efficacy studies for certain biosimilars
Regulatory NewsJoanne S. Eglovitch
Advanced therapies/cell and gene therapyBiologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsEuropeProduct developmentQuality Assurance and ControlRegulatory Intelligence/PolicyResearch, Design and Development